BioSpace News Archive

Impel NeuroPharma and Veeva Systems (NYSE: VEEV) today announced a strategic partnership as Impel continues advancing its pipeline of innovative medicines for central nervous system (CNS) diseases with high unmet needs.

Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq: NVCN / TSX: NVCN) announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of 36,000,000 common shares at a purchase price of US$2.00 per common share in a registered direct offering

Application Could Provide U.S. and International Patent Coverage for PL9643, Palatin’s Lead Compound for Dry Eye Disease Phase 2/3 Clinical Trial Currently Planned for Mid-2021

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at noon Eastern/ 9:00 a.m. Pacific.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it plans to release financial results for the fourth quarter and fiscal year ended December 31, 2020 before the market opens on March 9, 2021. The company will host a conference call at 8:30am Eastern Time on March 9, 2021

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)a clinical stage biopharmaceutical company focused on Artificial Intelligence driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis and liver disease, today announced the appointment of Todd M. Hobbs, M.D., to the newly created position of Chief Medical Officer

Creative Medical Technology Holdings announced today new data explaining mechanisms of action of its patented OvaStem® female infertility/ovarian failure treatment.

HemoShear Therapeutics, Inc., a clinical stage company developing treatments for rare metabolic disorders, has raised $40 million in a Series A financing.

New Partnership Provides Medical Mutual Members Access to More Comprehensive Diabetes Prevention, Diabetes Care, Hypertension Care, and Prevention Programs

This capital raising enables proceeding with the Phase 2b PTSD trial in mid-2021 as planned and sees the Company well capitalised